News Limited prostate cancer screening backed in UK A recommendation on prostate cancer screening has been delivered in the UK, upsetting patient groups whilst being endorsed by medical organisations.
News Advocate slams muted response to UK male health strategy A mental health campaigner has condemned the "stunning silence" from mainstream media in the UK as the first-ever men's health strategy is revealed.
News J&J swoops on cancer biotech Halda with $3bn takeover deal Johnson & Johnson has added to the flurry of M&A deals in pharma with an agreement to buy Halda Therapeutics and its RIPTAC anticancer platform.
News "Significant shift" as NICE widens prostate cancer drug use NICE has changed unpopular guidance on abiraterone for hormone-sensitive prostate cancer after the entry of generics into the UK market.
News As UK mulls prostate cancer screening, study shows benefit New data have shown that the balance between the benefits and harms of prostate cancer screening has improved with longer follow-up.
News As Blenrep returns, GSK adds another ADC to cancer pipeline GSK has boosted its pipeline of antibody-drug conjugates for cancer, licensing a prostate cancer candidate from Syndivia.
News Ambros' $125m for pain disorder drug, and other financings Our latest crop of biofinancings has nine-figure rounds for Ambros, Atavistik, Orum, and Addition, with Link Cell and Aeovian also raising new funds.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.